Towa Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter Ended December 2015; Reaffirms Earnings Guidance for the Full Year Ending March 2016
February 07, 2016
Share
Towa Pharmaceutical Co., Ltd. reported earnings results for the third quarter ended December 2015. For the quarter, the company reported net sales of JPY 61,234 million against JPY 53,055 million a year ago. Operating income was JPY 8,919 million against JPY 8,612 million a year ago. Ordinary income was JPY 8,929 million against JPY 12,506 million a year ago. Profit attributable to owners of parent was JPY 6,308 million against JPY 8,905 million a year ago. Capital expenditure was JPY 11.5 billion against JPY 13.8 billion a year ago.
For the full year ending March 2016, the company reaffirms net sales of JPY 82,000 million, operating income of JPY 11,500 million, ordinary income of JPY 11,500 million and profit attributable to owners of parent of JPY 8,200 million.
Towa Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The main products are generic drugs, which are launched after the efficacy and safety of new drugs have been confirmed for a certain period of time. It is a drug with the same effect, usage and dosage. The Company is involved in the sale and outsourced manufacture of products and generic drugs. The Company is involved in the research and outsourced manufacture of active pharmaceutical ingredient and soft capsules. The Company is also involved in the planning, development, contract manufacturing of health foods, general foods, miscellaneous goods and others.
Towa Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter Ended December 2015; Reaffirms Earnings Guidance for the Full Year Ending March 2016
TOWA PHARMACEUTICAL CO., LTD. 
